Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SSTR5 | P35346 | 6/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | NQO1 | P15559 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9971029 | 0.84 | PKM (0.53) | PKMKDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL3577502 | 0.84 | PKM (0.53) | PKMKDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL22778208 | 0.82 | PKM (0.49) | PKMKDM4EALDH1A1MAPK1SMN1; SMN2 | |
| Bromide SCHEMBL22778255 | 0.82 | PKM (0.49) | PKMKDM4EALDH1A1MAPK1SMN1; SMN2 | |
| Bromide SCHEMBL29525754 | 0.81 | PKM (0.48) | PKMKDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL31127512 | 0.80 | TUBB4A (0.37) | PKMKDM4ESMN1; SMN2SSTR5 | |
| SCHEMBL8563305 | 0.79 | PKM (0.50) | PKMKDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL14655775 | 0.79 | TAAR1 (0.56) | PKM | |
| SCHEMBL29543480 | 0.79 | TAAR1 (0.56) | PKM | |
| SCHEMBL20970874 | 0.77 | HTR2A (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1394150-B1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-1303490-B1 | N-OXIDES AS NK1 RECEPTOR ANTAGONIST PRODRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| CN-1256326-C | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | CN | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| US-6897226-B2 | NK-1 receptor active amine oxide prodrugs | HOFFMANN-LA ROCHE INC. (US) | 2005-05-24 | — | — | US | disclosed |
| CN-1178917-C | N-oxides of 4-phenyl-pyridine derivatives as NK1 receptor antagonist prodrugs | - | 2004-12-08 | — | — | CN | disclosed |
| US-6806370-B2 | NEUROKININ-1 RECEPTOR ANTAGONISTS ARE FURTHER USEFUL FOR THE TREATMENT OF MOTION SICKNESS AND FOR TREATMENT INDUCED VOMITING | HOFFMANN-LA ROCHE INC. | 2004-10-19 | — | — | US | disclosed |
| US-6747026-B2 | FOR THERAPY OF DISEASE RESPONSIVE TO ANTAGONIST MODULATION OF THE NEUROKININ-1 (NK-1) RECEPTOR IN A PATIENT | HOFFMAN-LA ROCHE INC. | 2004-06-08 | — | — | US | disclosed |
| US-20040048901-A1 | NK-1 receptor active amine oxide prodrugs | HOFFMANN TORSTEN (DE) | 2004-03-11 | — | — | US | disclosed |
| EP-1394150-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| EP-1035115-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-13 | — | — | EP | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| CN-1202152-A | Novel 4- (oxoxyphenyl) -3-oxopiperidines for the treatment of cardiac and renal insufficiency | HOFFMANN LA ROCHE (CH) | 1998-12-16 | — | — | CN | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| EP-0549366-B1 | Thiazolidine compounds containing a quinone group, their preparation and their therapeutic uses | SANKYO CO (JP) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
| EP-0549365-B1 | Thiazolidine compounds, their preparation and their therapeutic uses | SANKYO CO (JP) | 1995-08-09 | — | — | EP | disclosed |
| US-5338855-A | Treating diabetes or hyperlipemia | SANKYO COMPANY, LIMITED (JP) | 1994-08-16 | — | — | US | disclosed |
| EP-0549366-A1 | Thiazolidine compounds containing a quinone group, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1993-06-30 | — | — | EP | disclosed |
| EP-0549365-A1 | Thiazolidine compounds, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1993-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048901-A1 | NK-1 receptor active amine oxide prodrugs | TACR1, BDKRB1, NPSR1 | PKM 951/4885KDM4E 706/4885ALDH1A1 560/4885 |
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | PKM 2071/4885KDM4E 2501/4885ALDH1A1 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.